Bioventix PLC (AIM:BVXP)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 88.82M -45.1% |
| Revenue (ttm) | 13.12M -3.6% |
| Net Income | 7.58M -6.3% |
| EPS | 1.43 -6.3% |
| Shares Out | 5.22M |
| PE Ratio | 11.86 |
| Forward PE | 12.49 |
| Dividend | 1.50 (8.70%) |
| Ex-Dividend Date | Nov 6, 2025 |
| Volume | 460 |
| Average Volume | 6,618 |
| Open | 1,716.00 |
| Previous Close | 1,700.00 |
| Day's Range | 1,600.00 - 1,750.00 |
| 52-Week Range | 1,600.00 - 3,040.00 |
| Beta | 0.59 |
| RSI | 36.82 |
| Earnings Date | Mar 25, 2026 |
About Bioventix
Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. It offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, oncology, and miscellaneous indications; Pyrene 1-hydroxypyrene glucuronide (HOP-G) ELISA kit to monitor human exposure to industrial pollutants; and Pyrene (HOP-G) lateral flow kits for monitoring of at-risk individuals without laboratory equipment. The company also provides contract SMAs services; and industrial and environ... [Read more]
Financial Performance
In fiscal year 2025, Bioventix's revenue was 13.12 million, a decrease of -3.61% compared to the previous year's 13.61 million. Earnings were 7.58 million, a decrease of -6.33%.
Financial StatementsNews
AIM Market Roundup: Angle, Coyngar, Light Science Technologies
Angle, Coyngar, Light Science Technologies are today's top risers, while BioVentix, Great Western Mining take the biggest fall on AIM